Background:A new, simple, selective, precise, and stability-indicating high-performance thin-layer chromatographic method has been established for analysis of itraconazole (ITZ) in the bulk drug and in pharmaceutical formulations. Separation was achieved on aluminium plate precoated with silica gel 60F254 using Toluene : Chloroform : Methanol [5 : 5 : 1.5 (v/v)] as mobile phase. Densitometric analysis was performed at 260 nm.Result:Compact bands of ITZ were obtained at Rf 0.52 ± 0.02. Linearity (R2 = 0.9978), limit of detection (180.29 ng/band), limit of quantification (546.34 ng/band), recovery (98–102%), and precision (≤0.51%) were satisfactory. Drug was not degraded under neutral and alkaline hydrolysis, UV and photolytic degradation, under-elevated temperature, and humidity. ITZ is degraded under acidic hydrolysis and oxidative condition; the degraded products were well resolved from individual bulk drug response. Developed method can effectively resolve drug from its excipients in capsule dosage form. The specificity of the method was confirmed by peak purity of resolved peak.Conclusion:The method can be applicable for routine analysis of ITZ in pharmaceutical formulation as stability-indicating. Because the method can effectively separate the drug from its degradation products as well as excipients, it can be used as a stability-indicating method.

It is well acknowledged that carbon nanotubes (CNTs) are a potential new class of nanomaterials for technological advancement. The recent discovery of diverse kinds of carbon nanostructures has sparked interest in the potential applications of these materials in a variety of disciplines. Numerous distinct carbon nanotube (CNT) production methods have been developed, and their characterisation, separation, and manipulation of individual CNTs are now possible. Structure, surface area, surface charge, size distribution, surface chemistry, aggregation state, and purity of the samples all have a significant impact on the reactivity of carbon nanotubes, as does the purity of the samples. Currently, carbon nanotubes (CNTs) are being successfully used in the medicinal, pharmaceutical, and biomedical fields because of their large surface area, which makes them capable of adsorbing or conjugating with a wide range of therapeutic and diagnostic substances (drugs, genes, vaccines, antibodies, biosensors, etc.). They were the first to demonstrate that they are a great vehicle for drug delivery straight into cells without the need for metabolic processing by the body. This paper discusses the different types, structures, and properties of CNTs, as well as CNT synthesis and purification methods, how to functionalize CNTs, and their application in medicinal, pharmaceutical, and biomedical fields, toxicological properties and their assessment, as well as in-vivo pharmacology and biodegradation pathways.

The global pandemic produced by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first appeared in Wuhan, China, in December 2019 and which then spread rapidly, made it difficult to find or develop effective medications for its prevention and treatment. Therefore, the first stage is necessitating the use of a precise and quick diagnostic method to detect SARS-CoV-2 infected patient followed by effective patient isolation and the commencement of early treatment, which can range from supportive therapy to specialised medications such corticosteroids, antiviral medications, antibiotics, and the recently introduced convalescent plasma. Despite the extraordinary developments in advanced medicinal system, no confirmed viable medicines exist at this time. Rapid research on SARS CoV-2 epidemiology has led to the discovery of certain new targets for prospective therapeutic treatments. Many therapeutic options have been evaluated, and clinical studies are proceeding at a breakneck speed. However, there is a lot of room for more study into finding cost-effective and safer medicines, vaccinations, and measures to ensuring that COVID-19 preventive and treatment programmes are available to everyone. The goal of this study is to compile all of the current advancements in the worldwide medical system in the fight against COVID-19.

No abstract

Background: Quantitative characterisation of any contagious diseases could help in making effective strategy to prevent further spreading of the disease. Despite the rapid research in prevention of spreading COVID-19, yet there is no quantitatively information about spatiotemporal epidemiology and epidemic intensity of COVID-19. Therefore, we aimed to quantitatively characterize spatiotemporal epidemiology and epidemic intensity of COVID-19 in Indian geography by determine it’s infectability rate, efficacy rate, transmission rate and likelihood of total populations to be infected with COVID-19 in India. Method: Novel statistical model was designed to quantitatively characterize spatiotemporal epidemiology and epidemic intensity of COVID-19. A Retrospective Cohort study was carried out online and offline in Indian geography using a COVID-19 transmission questionnaires sheet that comprises five mandatory questions. The collected offline as well as online data was then entered into a Microsoft excel sheet to obtain primary data and secondary data required for the mathematical model to calculate quantitative data of spatiotemporal epidemiology and epidemic intensity of COVID-19 in India geography. Result and Discussion: Total 539 responses were analysed in the current study out of 557 received responses between April-2021 to May-2021. Average reproductive number of secondary cases was found 0.77. Infectability rate of COIVD-19 patient was found 38.11% while healthy person has 21.08% risk of becoming infected if they expose to the Primary case. J-Index and H-Index were found 55.32% and 4.44%, respectively, indicating that COVID-19 disease outbreaks as severe epidemic disease in India and has potential to infect ~4.44% Indian population. Conclusion: Higher infectability rate (38.11%) of COIVD-19 patient and higher efficacy rate (21.08%) of healthy individual to be infected with COVID-19 outbreak it a severe epidemic in India. COVID-19 potential to infect about 4.44% India

Background: Quantitative characterisation of any contagious diseases could help in making effective strategy to prevent further spreading of the disease. Despite the rapid research in prevention of spreading COVID-19, yet there is no quantitatively information about spatiotemporal epidemiology and epidemic intensity of COVID-19. Therefore, we aimed to quantitatively characterize spatiotemporal epidemiology and epidemic intensity of COVID-19 in Indian geography by determine it’s infectability rate, efficacy rate, transmission rate and likelihood of total populations to be infected with COVID-19 in India. Method: Novel statistical model was designed to quantitatively characterize spatiotemporal epidemiology and epidemic intensity of COVID-19. A Retrospective Cohort study was carried out online and offline in Indian geography using a COVID-19 transmission questionnaires sheet that comprises five mandatory questions. The collected offline as well as online data was then entered into a Microsoft excel sheet to obtain primary data and secondary data required for the mathematical model to calculate quantitative data of spatiotemporal epidemiology and epidemic intensity of COVID-19 in India geography. Result and Discussion: Total 539 responses were analysed in the current study out of 557 received responses between April-2021 to May-2021. Average reproductive number of secondary cases was found 0.77. Infectability rate of COIVD-19 patient was found 38.11% while healthy person has 21.08% risk of becoming infected if they expose to the Primary case. J-Index and H-Index were found 55.32% and 4.44%, respectively, indicating that COVID-19 disease outbreaks as severe epidemic disease in India and has potential to infect ~4.44% Indian population. Conclusion: Higher infectability rate (38.11%) of COIVD-19 patient and higher efficacy rate (21.08%) of healthy individual to be infected with COVID-19 outbreak it a severe epidemic in India. COVID-19 potential to infect about 4.44% Indian population, at present, COVID-19 already infected ~2.13% Indian population, which is about 50% of the anticipated population to be infected i.e., 4.44%.

A novel stability-indicating, reversed-phase, high-performance liquid chromatography (RP-HPLC) method was developed and validated for the determination of favipiravir in an oral suspension. The effective separation of favipiravir and its degradation products was achieved on a Zorbax Eclipse Plus C18 column (5 μm particle size, 150 mm length × 4.6 mm diameter). The mobile phase was prepared by mixing 5 mM of phosphate buffer (pH 3.5) and methanol in a 75:25 v/v ratio delivered at a 1.0 mL/min flow rate. The eluents were monitored using a photodiode array detector at a wavelength of 322 nm. The stability-indicating nature of this method was evaluated by performing force degradation studies under various stress conditions, such as acidic, alkali, oxidative, thermal, and photolytic degradation. Significant degradation was observed during the alkali stress degradation condition. The degradation products generated during various stress conditions were well separated from the favipiravir peak. In addition, the major degradation product formed under alkali stress conditions was identified using UPLC-ESI-TQ-MS/MS and NMR. Method validation was performed according to the ICH Q2 (R1) guideline requirements. The developed method is simple, accurate, robust, and reliable for routine quality control analysis of favipiravir oral suspensions.

The goal of the current study is to develop and validate a new chromatographic method for Fosfomycin Trometamol's determination in both pure form and pharmaceutical formulation. In the present study, a pre chromatographic derivatization of Fosfomycin Trometamol was done by forming an ion-pair complex of Heterocyclic nitrogen using the acidic dye methyl orange and phthalate buffer of pH-6. The yellow ion-pair complex was extracted with chloroform and it was further extracted with aqueous solution of 0.01M HCL. The ion-pair complex of Fosfomycin Trometamol and methyl orange obeyed Beer's law in the range of 30 -70 μg/ml with a correlation coefficient (r2) of 0.9946. A Liquid chromatography system equipped with an Agilent ACE C18 column (250 X 4.6mm, 5μm) was used as a stationary phase in this work. The developed method was validated according to ICH guidelines. For determining the medication in bulk and formulation, the devised approach was proven to be accurate, sensitive, and repeatable